Products
Givastomig Biosimilar Bispecific Antibody (Claudin-18 × 4-1BB) for Research
Cat No.: GMP-Bios-INN-1217
Anti-CLDN18 therapeutic antibody (Pre-made Givastomig biosimilar,Bispecific (G1-scFv_L-kappa)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Givastomig (development codes TJ-033721/TJ-CD4B) is a bispecific antibody targeting claudin 18.2 (CLDN18) and TNFRSF9 (4-1BB). It is developed by I-MAB Biopharma for solid tumors and colorectal cancer. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1217-1mg | 1mg | |
| GMP-Bios-INN-1217-10mg | 10mg | |
| GMP-Bios-INN-1217-100mg | 100mg | |
| GMP-Bios-INN-1217-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Givastomig biosimilar, Bispecific (G1-scFv_L-kappa), Anti-CLDN18;TNFRSF9/CD137/4-1BB Antibody: Anti-SFTA5/SFTPJ/TNFRSF9/CD137 therapeutic antibody |
| INN Name | Givastomig |
| Target | CLDN18;TNFRSF9/CD137/4-1BB |
| Format | Bispecific (G1-scFv_L-kappa) |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | I-MAB |
| Conditions Approved | na |
| Conditions Active | Solid tumours;Colorectal cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
